You are here

Bioiberica participated at two scientific symposia hosted jointly by Indonesia’s Medical and Pharmaceutical Associations

2 May 2017
Healthcare

This past month in Jakarta more than 500 professionals attended two meetings for primary care physicians and pharmaceutics
Dr. Laia Montell, head of pre-clinical research at Bioiberica, presented the most recent scientific results on the efficacy of the combination of chondroitin sulfate and glucosamine

The public demand for an improved healthcare service is the driving force behind the Medtech 2017 and Disease Update & CPD Online symposia for primary care physicians and pharmaceutics, respectively. Both events are held annually at Jakarta in a joint effort of the Medical and Pharmaceutical Associations of Indonesia.

During the sessions on the 25th of March, osteoarthritis had a highlighted position, for it is a disease which impacts public healthcare in an important way. “Osteoarthritis is a disease with an enormous social impact, for it seriously affects productivity”, said Dr. Adeng Fathurrahman Hanafi, president of the Jakarta Apothecary Symposium Committee.

At this symposium Bioiberica presented two lectures on osteoarthritis, which included the presentation of the most recently published scientific evidence proving the efficacy and security of the combination of chondroitin sulfate (CS) and glucosamine. These results put particular emphasis on the idea that “not all CSs are the same”.

There is a high variability, due to differences in raw material quality, extraction and purification techniques of chondroitin sulfate, which produces molecules having different biological effects, thus compromising the efficacy and safety of the final product. The reference product should be a pharmaceutical grade chondroitin sulfate of the highest purity, and well proven clinical efficacy”, explained Dr. Laia Montell, head of pre-clinical research at Bioiberica.

They also discussed the latest guidelines of the international societies specializing in the treatment of osteoarthritis, which highly recommend these products, and explained the molecular mechanism that causes its therapeutic effect.

Indonesian media provided major coverage of the symposium, with the presentations being attended by more than 500 attendees who crowded the Conventions Hall and expressed keen interest in the topics discussed, asking a number of questions at the close of the presentation. 

Bioiberica